Premium
Delivery of quinolone antibacterials to turbot, Scophthalmus maximus (L.), via bioencapsulation: quantification and efficacy trial
Author(s) -
DUIS K.,
HAMMER C.,
BEVERIDGE M. C. M.,
INGLIS V.,
BRAUM E.
Publication year - 1995
Publication title -
journal of fish diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 85
eISSN - 1365-2761
pISSN - 0140-7775
DOI - 10.1111/j.1365-2761.1995.tb00298.x
Subject(s) - turbot , oxolinic acid , scophthalmus , biology , vibrio anguillarum , flumequine , microbiology and biotechnology , antibiotics , pharmacology , vibrio , fishery , enrofloxacin , bacteria , fish <actinopterygii> , ciprofloxacin , nalidixic acid , genetics
. The incorporation of the quinolone antibacterials oxolinic acid and sarafloxacin into Artemia fransciscana and subsequently into turbot, Scophthalmus maximus (L.), was quantified, and the therapeutic efficacy of the bioencapsulated drugs against challenge with Vibrio anguillarum 8587 was investigated. Five‐week‐old turbot were fed for 10 days with Artemia enriched with either oxolinic acid or sarafloxacin. Therapeutic concentrations were reached with both drugs (11.8 μg oxolinic acid per gram fresh weight: 1.8 μg sarafloxacin per gram fresh weight). Both treatments proved effective against challenge, with V. anguillarum ‐specific mortality rates of 6 and 14% in the oxolinic acid and sarafloxacin treated groups, respectively, compared with 75% in the infected control. However, incorporation of the drug by brine shrimp was extremely low (<1%), and therefore, bioencapsulation cannot be considered as an appropriate method to reduce impact on the environment.